Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 15/20 | 1.00 |
| ▸ | CTSL | P07711 | 5/20 | 0.75 |
| ▸ | CTSB | P07858 | 2/20 | 0.75 |
| ▸ | CTSF | Q9UBX1 | 2/20 | 0.75 |
| ▸ | CTSV | O60911 | 1/20 | 0.75 |
| ▸ | CTSS | P25774 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23874957 | 1.00 | CTSK (1.00) | CTSKCTSLCTSBCTSFCTSV | |
| SCHEMBL4987203 | 1.00 | CTSK (1.00) | CTSKCTSLCTSBCTSFCTSV | |
| SCHEMBL4590757 | 1.00 | CTSK (1.00) | CTSKCTSLCTSBCTSFCTSV | |
| SCHEMBL21645296 | 1.00 | CTSK (1.00) | CTSKCTSLCTSBCTSFCTSV | |
| SCHEMBL5742250 | 0.91 | CTSK (0.85) | CTSKCTSLCTSBCTSFCTSV | |
| SCHEMBL4986789 | 0.90 | CTSK (0.82) | CTSKCTSLCTSBCTSFCTSV | |
| SCHEMBL2155710 | 0.90 | CTSK (0.82) | CTSKCTSLCTSBCTSFCTSV | |
| SCHEMBL21690159 | 0.90 | CTSK (0.82) | CTSKCTSLCTSBCTSFCTSV | |
| SCHEMBL2155451 | 0.90 | CTSK (0.82) | CTSKCTSLCTSBCTSFCTSV | |
| SCHEMBL23875152 | 0.90 | CTSK (0.82) | CTSKCTSLCTSBCTSFCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO., INC. (US) | 2023-05-11 | — | — | US | claimed |
| EP-4149552-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG | Healion Bio, Inc. (US) | 2023-03-22 | — | — | EP | claimed |
| WO-2022072504-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| US-20150250759-A1 | COMPOSITION FOR INHIBITION OF CATHEPSIN K | MERCK SHARP & DOHME CORP. (US) | 2015-09-10 | — | — | US | claimed |
| EP-2783687-A1 | Composition for inhibition of cathepsin K | Merck Sharp & Dohme Corp. (US) | 2014-10-01 | — | — | EP | claimed |
| US-20140186471-A1 | COMPOSITION FOR INHIBITION OF CATHEPSIN K | MERCK SHARP & DOHME (US) | 2014-07-03 | — | — | US | claimed |
| EP-1817276-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK CANADA INC (CA) | 2012-08-08 | — | — | EP | claimed |
| US-20080255072-A1 | Oral unit dose for inhibiting bone resorption; reduced frequency regime; N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide; blister pack card orienting the dosages in the order of their intended use | MERCK SHARP & DOHME LLC | 2008-10-16 | — | — | US | claimed |
| US-7407959-B2 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA & CO. (CA) | 2008-08-05 | — | — | US | claimed |
| US-20070293578-A1 | Cathepsin Cysteine Protease Inhibitors | GAUTHIER JACQUES Y | 2007-12-20 | — | — | US | claimed |
| US-20060111440-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2006-05-25 | — | — | US | claimed |
| WO-2023132842-A1 | DRUG COMBINATION TO TREAT MICROBIAL INFECTIONS INCLUDING CORONAVIRUS | AiPharma Global Holdings LLC (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO., INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4149552-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG | Healion Bio, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| WO-2022072504-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| US-20070293578-A1 | Cathepsin Cysteine Protease Inhibitors | GAUTHIER JACQUES Y | 2007-12-20 | — | — | US | disclosed |
| US-20070293578-A1 | Cathepsin Cysteine Protease Inhibitors | GAUTHIER JACQUES Y | 2007-12-20 | — | — | US | disclosed |
| US-20060111440-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2006-05-25 | — | — | US | disclosed |
| US-20060111440-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2006-05-25 | — | — | US | disclosed |
| US-20060111440-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | CTSV, CTSB, CTSS | CTSK 11/4885CTSL 13/4885CTSB 2/4885 |
| US-20060111440-A1 | Cathepsin cysteine protease inhibitors | CTSB, CTSS, CTSZ | CTSK 4/4885CTSL 8/4885CTSB 1/4885 |
| US-20140186471-A1 | COMPOSITION FOR INHIBITION OF CATHEPSIN K | CTSK, CTSB, CTSZ | CTSK 1/4885CTSL 12/4885CTSB 2/4885 |
| US-20080255072-A1 | Oral unit dose for inhibiting bone resorption; reduced frequency regime; N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide; blister pack card orienting the dosages in the order of their intended use | CTSK, CTSB, CTSE | CTSK 1/4885CTSL 7/4885CTSB 2/4885 |
| US-20150250759-A1 | COMPOSITION FOR INHIBITION OF CATHEPSIN K | CTSK, CTSB, CTSZ | CTSK 1/4885CTSL 12/4885CTSB 2/4885 |
| US-20070293578-A1 | Cathepsin Cysteine Protease Inhibitors | CTSB, CTSS, CTSE | CTSK 7/4885CTSL 10/4885CTSB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.